The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To evaluate possible associations between epidemiological and clinical data with risk of levodopa-induced dyskinesias (LID) onset in Parkinson’s disease (PD) patients. Background: LID are…Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.
Objective: To describe the occurrence, diagnostic approach, clinical management and outcome of diphasic dyskinesias (Dyskinesias-Improvement-Dyskinesias, DID) in a large group of Parkinson’s Disaese (PD) patients…Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)
Objective: To compare levodopa PK, derived from ND0612 (a proprietary liquid levodopa/carbidopa formulation designed for subcutaneous (SC) administration) with Levodopa/Carbidopa Intestinal Gel (LCIG). Background: While…Developing a new home monitoring device for dyskinesia in Parkinson’s disease
Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios
Objective: To determine predictors of response and conversion ratios for a novel extended release levodopa preparation. Background: A new extended release levodopa preparation, Rytary®, has…Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience
Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients
Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch
Objective: To determine whether smartwatch sensor data correlates with clinician-measured Parkinson's disease symptoms. Background: Data collected with smartwatches could be used for long-term, continuous assessment…Automated Telehealth Diagnostics for Remote Parkinson Monitoring
Objective: To clinically assess and evaluate the impact of automated telehealth diagnostics on patients with Parkinson's disease (PD). Background: A single evaluation in a clinical…
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 62
- Next Page »